View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 8, 2021updated 07 Jan 2022 5:36am

Alvotech and Oaktree enter merger deal to form biopharma company

To be valued at nearly $2.25bn, the combined firm is expected to invest in boosting the biosimilar pipeline.

Alvotech has signed a definitive merger agreement with special purpose acquisition company Oaktree Acquisition Corp II to form a publicly traded international biopharmaceutical company.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

With an initial enterprise cost of nearly $2.25bn, the merged entity is expected to advance investments to grow its pipeline of biosimilars.

The deal is anticipated to offer gross proceeds of over $450m to Alvotech, which includes over $150m from private placement (PIPE) investors and cash proceeds of nearly $250m held in Oaktree Acquisition’s trust account.

The PIPE investors comprise funds handled by Suvretta Capital, Athos, CVC Capital Partners and Temasek among others and a $50m equity offering from the current stakeholders.

Under the deal, present stakeholders of Alvotech will offer complete equity into the merged company and own nearly 80% of the combined company.

Stakeholders of Oaktree Acquisition and PIPE investors will own nearly 11% and 7% of the issued and outstanding ordinary shares, respectively, on concluding the deal.

Alvotech CEO Mark Levick said: “Alvotech is in a unique position to impact the global healthcare ecosystem in a positive way and transform patients’ lives.

“Biosimilar medicines can increase access for patients whilst lowering cost for healthcare systems and that helps to align our mission with all of our stakeholders.”

The boards of directors of both companies unanimously accepted the business combination deal.

Subject to necessary closing conditions and approvals, the deal is anticipated to conclude in the first half of next year.

Established in 2013 in Iceland, Alvotech develops and produces biosimilar therapies for patients globally.

At present, the company’s pipeline has seven products across various therapeutic areas.

Alvotech has collaborated with various pharmaceutical firms, including Teva Pharmaceutical in the US and Stada in the EU and has collected up to $1.15bn licence fee payments by 30 June.

In August last year, Alvotech signed an exclusive strategic partnership with Teva to market five biosimilar candidates in the US.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology